Multidrug-resistant tuberculosis among previously treated patients in the Philippines

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 5, 2011, Pages 652-656

  Gler, Maria Tarcela ^a   Macalintal, L E ^a   Raymond, L ^a   Guilatco, R ^a   Quelapio, M I D ^a   Tupasi, T E ^a  

^a MAKATI MEDICAL CENTER   (Philippines)

Author keywords

Category 1 failures; High burden country; MDR TB; Previously treated

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; DRUG TREATMENT FAILURE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; PHILIPPINES; PREVALENCE; PRIORITY JOURNAL; RELAPSE;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHILIPPINES; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79954523528     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0400     Document Type: Article

References (21)

1. Caminero J A. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-390.
2. Mendoza M T, Gonzaga A J, Roa C, et al. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippines General Hospital, Manila, Philippines. Int J Tuberc Lung Dis 1997; 1: 59-63. (Pubitemid 127509687)
3. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
4. Watt G, Selkon J B, Bautista S, Laughlin L W. Drug-resistant TB meningitis in the Philippines. Tubercle 1989; 70: 139-141.
5. Tupasi T E, Radhakrishna S, Rivera A B, et al. The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. Int J Tuberc Lung Dis 1999; 3: 471-477.
6. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
7. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2009.
8. Kent T K, Kubica G P. Public health mycobacteriology. A guide for the level III laboratory. Atlanta, GA, USA: Centers for Disease Control, 1985: p 168.
9. Wayne L G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis 1974; 109: 147-151.
10. Department of Health, The Philippines. Guidelines for the implementation of the programmatic management of drug-resistant tuberculosis, May 26, 2008. 10 AO 2008-0018. Manila, The Philippines: DoH, 2008.
11. Trébucq A, Anagonou S, Gninafon M, Lambregts K, Boulahbal F. Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs in Benin after 12 years of short-course chemotherapy. Int J Tuberc Lung Dis 1999; 3: 466-470.
12. Chavez Pachas A M, Blank R, Smith Fawzi M C, et al. Identifying early treatment failure on category 1 therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8: 52-58. (Pubitemid 38120706)
13. Heldal E, Arnadottir T, Cruz J R, Tardencilla A, Chacon L. Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients. Int J Tuberc Lung Dis 2001; 5: 129-136.
14. Kritski A L, Sergio L, de Jesus R, Andrade M K, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
15. Becerra M C, Freeman J, Bayona J, Shin S S, Kim J Y. Using treatment failure under effective direct observed treatment short-course chemotherapy program to identify multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114. (Pubitemid 30123642)
16. Auer C, Lagahid J, Roa C, et al. Retreatment TB patients treated in a public DOTS programme: who among them is likely to have poor treatment outcome? Int J Tuberc Lung Dis 2005; 9 (Suppl 1): S306.
17. World Health Organization. Global TB control 2007: surveillance, planning, financing. WHO report 2007. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
18. World Health Organization. Global TB control 2009: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
19. Chiang C Y, Schaaf H S. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 672-682.
20. Caminero J A. A TB guide for specialist physicians. Paris, France: International Union Against Tuberculosis and Lung Disease, 2004.
21. World Health Organization. Framework for implementing new TB diagnostics July 2010 (pre-publication copy). Geneva, Switzerland: WHO, 2010. http://www.tbevidence.org/documents/policies/whopolicyframework-july10.pdf Accessed February 2011.